Cereno Scientific Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Cereno Scientific'in gelirinin yıllık 171.4% oranında azalacağı tahmin edilmektedir. EPS'nin büyümesi yıllık 20.5% oranında artması beklenmektedir.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

20.5%

EPS büyüme oranı

Biotechs kazanç büyümesi	49.2%
Gelir büyüme oranı	-171.4%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	12 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

OM:CRNO B - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (SEK Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	N/A	N/A	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
6/30/2024	69	-69	-118	-49	N/A
3/31/2024	55	-59	-102	-46	N/A
12/31/2023	49	-48	-86	-37	N/A
9/30/2023	53	-35	-83	-30	N/A
6/30/2023	58	-31	-93	-35	N/A
3/31/2023	65	-27	-86	-21	N/A
12/31/2022	58	-28	-76	-19	N/A
9/30/2022	52	-23	-74	-22	N/A
6/30/2022	51	-19	-79	-9	N/A
3/31/2022	49	-18	-64	-16	N/A
12/31/2021	45	-16	-58	-13	N/A
9/30/2021	31	-17	-44	-13	N/A
6/30/2021	23	-17	-15	-12	N/A
3/31/2021	9	-16	-23	-14	N/A
12/31/2020	8	-16	-24	-16	N/A
9/30/2020	0	0	7	6	N/A
6/30/2020	-1	0	7	6	N/A
3/31/2020	0	1	-3	-3	N/A
12/31/2019	0	-1	-1	-1	N/A
9/30/2019	10	-16	-32	-22	N/A
6/30/2019	10	-16	-32	-20	N/A
3/31/2019	9	-15	-19	-9	N/A
12/31/2018	7	-12	-17	-9	N/A
9/30/2018	6	-9	-15	-7	N/A
6/30/2018	9	-8	-16	-7	N/A
3/31/2018	9	-6	N/A	-5	N/A
12/31/2017	9	-5	N/A	-4	N/A
9/30/2017	9	-4	N/A	-3	N/A
6/30/2017	6	-4	N/A	-5	N/A
3/31/2017	6	-6	N/A	-6	N/A
12/31/2016	5	-6	N/A	-5	N/A
9/30/2016	3	-5	N/A	-7	N/A
6/30/2016	3	-4	N/A	-4	N/A
3/31/2016	1	-1	N/A	-1	N/A
12/31/2015	1	0	N/A	-1	N/A
8/31/2015	0	0	N/A	0	N/A
8/31/2014	1	0	N/A	0	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CRNO B 'un tahmini kazanç büyümesinin tasarruf oranının ( 1.2% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: CRNO B 'un kazançlarının Swedish pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: CRNO B şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: CRNO B gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: CRNO B gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CRNO B 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Cereno Scientific Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Cereno Scientific Announces Initiation of Multiple Ascending Dose (MAD) Part of Phase I Trial of the Novel HDAC Inhibitor CS014

Cereno Scientific AB (publ) to Report Q2, 2025 Results on Aug 27, 2025

Cereno Scientific AB (publ) Selects Rare Disease Idiopathic Pulmonary Fibrosis as the Initial Target Indication for Novel HDACi CS014

Is Cereno Scientific (STO:CRNO B) Using Debt Sensibly?

Cereno Scientific AB (publ) Announces New Preclinical Data Demonstrates Dose Dependent Positive Impact on Reversal of Pulmonary Vascular Remodeling

Cereno Scientific AB Announces Changes in the Nomination Committee's Composition for the Annual General Meeting 2025

No independent directors

Cereno Scientific AB Announces New Preclinical Data for Cereno Scientific's Novel IP Receptor Agonist CS585 Presented at ESC Congress 2024

Cereno Scientific Receives Orphan Medicinal Product Designation in the Eu for Cs1 in Rare Disease Pulmonary Arterial Hypertension

Cereno Scientific AB (publ), Annual General Meeting, Jun 17, 2025

Cereno Scientific Expands Patent Protection for PAH Drug Candidate CS1's Third Patent Family in Brazil

First Subject Dosed in Cereno Scientifics First-In-Human Phase I Trial of Novel Hdac Inhibitor Cs014

Cereno Scientific Receives Approval from, EMA to Initiate First-In-Human Phase I Trial with Novel Epigenetic HDAC Inhibitor, CS014

New major risk - Financial position

Cereno Scientific AB (publ) to Report Q1, 2025 Results on May 22, 2025

Cereno Scientific AB (Publ) Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025

Cereno Scientific AB (publ), Annual General Meeting, Apr 16, 2024

Cereno Scientific AB (Publ) Approves Election of New Directors

Cereno Scientific AB Submits Clinical Trial Application (CTA) for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH

Director exercised options to buy kr1.0m worth of stock.

Cereno Scientific Appoints Don De Bethizy as Board of Directors

Cereno Scientific Publishes Update and Study Protocol for the FDA Approved Expanded Access Program for CS1 in PAH

Cereno Scientific Reports One New Patient Enrolled, One Additional Patient Randomized, and One Additional Patient Completed in the Phase II Study of CS1 in PAH

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Reports Progress of Expanded Access Program and Announces Timeline Adjustment in the Phase II Study of CS1 in PAH

New minor risk - Market cap size

Cereno Scientific AB Appoints Rahul Agrawal as Chief Medical Officer and Head of R&D

Cereno Scientific AB (publ) Appoints Megha Ranjan as Project Director to Strengthen Business Capabilities

Cereno Scientific AB Appoints Julia Fransson as Director of Business Development

Cereno Scientific Receives Expanded Access by the FDA to Drug Candidate CS1 for Rare Disease Pulmonary Arial Hypertension

Cereno Scientific Strengthens R&D with Recruitment of Tatiane Abreu Dall'Agnol as Medical Director

Cereno Scientific AB Confirms New Clinic Activated in the Phase II Study of Drug Candidate CS1 in Rare Disease PAH

Cereno Scientific AB (publ) to Report Q3, 2024 Results on Nov 21, 2024

Cereno Scientific's Novel HDACi CS014 Has Potential to Become an Effective Antithrombotic Therapy in Patients with A High Risk of Thrombotic Events as Presented at the ASH Meeting

Cereno Scientific Announces New Preclinical Data Concludes That Drug Candidate CS585

Cereno Scientific Completes Preclinical Safety Program for Innovative Drug Candidate CS014 Targeting Thrombosis Prevention and Reaches A Major Preparatory Milestone Towards the Phase I Study

Cereno Scientific Obtains First Patent in India for Drug Candidate Cs1 Through Its Third Patent Family

Cereno Scientific AB (Publ) Move to Request “Compassionate Use” of CS1 for Treatment of Patients with Rare Disease PAH

New major risk - Financial position

Third quarter 2023 earnings released

Cereno Scientific Reports Significant Progress and A Time Time Adjustment in the Phase II Study of CS1 in Rare Disease PAH

Cereno Scientific AB (publ) Appoints Jeppe Øvlesen as a New Board Member

Cereno Scientific AB (Publ) Reports Positive Results from the Data Quality Control Review Initiative in the Phase II Study of CS1 in Rare Disease Pul Arterial Hypertension (PAH)

Cereno Scientific Announces Appointments to the Nomination Committee Ahead of the Annual General Meeting 2024

New major risk - Shareholder dilution

Will Cereno Scientific (STO:CRNO B) Spend Its Cash Wisely?

Chief Medical Officer recently bought kr208k worth of stock

Second quarter 2023 earnings released

Cereno Scientific to Open Two New Clinics to Complete Patient Recruitment in the Phase II Study of CS1 in Pah

Cereno Scientific AB (Publ) Appoints Eva Jagenheim as Chief Financial Officer

Cereno Scientific Reports Positive Data from Patient Case Study

Chairperson recently bought kr804k worth of stock

Cereno Scientific Reports an Investigator-Initiated Patient Case Study from the Ongoing Phase II Study of CS1 in PAH

Cereno Scientific AB (publ), Annual General Meeting, Jun 03, 2024

Cereno Scientific Shares Progress Update in the Phase II Study with Drug Candidate CS1 in the Rare Disease PAH

Cereno Scientific's Phase II Study in the Rare Disease PAH Reports Two Patients Successfully Completed the Treatment Period with Drug Candidate CS1

Full year 2022 earnings released: kr0.20 loss per share (vs kr0.15 loss in FY 2021)

We're Keeping An Eye On Cereno Scientific's (NGM:CRNO B) Cash Burn Rate

Full year 2022 earnings released: kr0.26 loss per share (vs kr0.15 loss in FY 2021)

Cereno Scientific AB (publ) Reports Progress with CS1 Phase II Study in Pulmonary Arterial Hypertension

Cereno Scientific AB (publ) to Report Nine Months, 2023 Results on Nov 17, 2023

Cereno Scientific AB (Publ) Appoints Etienne Adriansen to Chief Business Officer, as of March 1, 2023

Cereno Scientific Announces Changes in the Executive Management Team

Cereno Scientific Reports Six Activated Clinical Sites and Updated Timeline in the Phase II Study in PAH with Drug Candidate CS1

Cereno Scientific AB (Publ) Announces Appointment of Nomination Committee

Third quarter 2022 earnings released: kr0.069 loss per share (vs kr0.047 loss in 3Q 2021)

No independent directors

Cereno Scientific's Patent Protection for Drug Candidate CS1 Expands in Mexico Through Its Second Patent Family

Cereno Scientific Reports First Patient Dosed in Phase II Study in PAH with Drug Candidate CS1

Second quarter 2022 earnings released

Cereno Scientific's Innovative Phase II Study Design in PAH with CS1 is Accepted for Presentation at the CHEST Annual Meeting on Oct. 16-19 in Nashville, US

Cereno Scientific Announces Enrolling the First Patient in Its Phase II Clinical Study with Lead Drug Candidate Cs1 in Pulmonary Arterial Hypertension

Cereno Scientific Reports First Patient Enrolled in Phase II Study in PAH with Drug Candidate CS1